Joe Rogan, who hosts one of the most popular podcasts on Spotify, wrongly claimed that the Pfizer and Moderna COVID-19 vaccines are "really gene therapy," conflating the vaccines pioneering mRNA technology with the experimental technique that involves modifying genes to treat or cure disease.
The inaccurate claim came about 51 minutes into the Aug. 20 episode of "The Joe Rogan Experience" as Rogan discussed the vaccines with guest Meghan Murphy, a Canadian freelance writer and journalist.
Heres what Rogan said:
"It's not really a vaccine in the traditional sense. A vaccine is where they take a dead virus, and they turn it into a vaccine, and they inject it into your body so that your body fights off it develops the antibodies, and your body understands what that is, whether it's the measles or polio, it knows how to fight it off.
"This is really gene therapy. It's a different thing. Its tricking your body into producing spike protein and making these antibodies for COVID. But its only good for a few months, theyre finding out now. The efficacy wanes after five or six months. Im not saying that people shouldnt take it. But Im saying, youre calling it a thing that its not. Its not exactly what youre saying it is, and youre mandating people take it."
Theres no national mandate requiring that all Americans get vaccinated against COVID-19, although many employers and university systems are requiring it. And Rogan based his claim about the COVID-19 vaccines partly on an outdated conception of what a vaccine is.
But the bigger problem with the claim is that it mischaracterizes the technology used by the Pfizer and Moderna vaccines. The technology does not amount to gene therapy, public health experts said.
"It's absolutely incorrect to say that vaccines are really gene therapy," said Cindy Prins, clinical associate professor of epidemiology at the University of Florida. "Vaccines don't make any changes to your own DNA, so they don't edit your own DNA like gene therapy does. They also don't replace any mutated genes in your body."
No genetic material enters the part of the cell that hosts DNA as a result of the mRNA vaccines.
Rogan and Spotify did not offer on-the-record comments for this fact-check.
How the mRNA COVID-19 vaccines work
The Centers for Disease Control and Prevention defines a vaccine as "a product that stimulates a persons immune system to produce immunity to a specific disease."
"Basically, a vaccine is a way to get your immune system to recognize something and create antibodies to it," said Richard Watanabe, professor of population and public health sciences at the University of Southern California.
The Pfizer and Moderna vaccines fit that definition, the CDC says. While they work differently than many other familiar vaccines relying on messenger RNA, or mRNA, technology they still trigger an immune response inside the body, offering vital protection.
Older methods of vaccination included inoculating people with inactivated versions of viruses, and some vaccines for other diseases still work that way. But that method has proven at times to be risky, Watanabe said, citing the infamous "Cutter Incident" of 1955, in which some polio vaccines were not properly inactivated and tens of thousands of people were accidentally injected with the live virus.
The mRNA technology in the Pfizer and Moderna COVID-19 vaccines is newer, though research on it dates back to the 1990s.
The vaccines work by instructing the cells to make versions of a harmless spike protein found on the surface of the coronavirus, so the immune system can recognize the protein and mount an antibody response against the virus in the event of a future infection, the CDC says.
The third COVID-19 vaccine available in the U.S., from Johnson & Johnson, delivers similar instructions using an adenovirus thats been altered to make it harmless.
"Its true that mRNA vaccines are a major departure from traditional vaccines," said Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security. "They contain just the genetic material of the gene of interest in the pathogen that codes for the protein needed for immunity. Thats what makes them so path-breaking."
The mRNA vaccine technology isnt really gene therapy
While both mRNA vaccination and gene therapy involve genetic technology, they are different things, experts said.
Gene therapy involves modifying a persons genes to cure or treat a disease, according to the Food and Drug Administration. The FDA says it can work by replacing a disease-causing gene in the body with a healthy version, turning off the disease-causing gene, or introducing a new gene entirely. Only a few gene therapies have been fully approved, said Prins.
"Gene therapy is used to replace or fix genetic mutations that lead to diseases like cystic fibrosis, neuromuscular disease, inherited blindness and other genetic conditions," Prins said. "Gene therapy is not used in vaccines at all, since vaccines don't replace or edit your own genes."
Gene therapy corrects a genetic defect by delivering the gene, or DNA, to the nucleus, the part of the cell where DNA is located, Adalja said.
The mRNACOVID-19 vaccines are designed around the genetic structure of the virus. They carry mRNA, which teaches the immune system to identify the coronavirus, but they do not alter the recipients genetic makeup or DNA. The mRNA strands never enter the nucleus of the cell after vaccination.
To cross into the nucleus, the mRNA chains from the shots would need a special enzyme, according to WebMD. And they would need another enzyme to be integrated into the DNA. They dont have those enzymes.
"Its really just a different approach to delivering what the immune system needs to see in order to create the antibodies," Watanabe said of the mRNA vaccines.
The mRNA strands also break down shortly after entering the body, unlike with gene therapy, Prins said.
"It sticks around in the cell only long enough to be used as a recipe to make some spike protein that the immune system can then detect and respond to," Prins said. "After a few days, your cells will break up that mRNA into small pieces. So the recipe gets torn up. The spike protein that was made will stay around a little longer, up to a few weeks, which helps you build that immune response. But it will also get broken down so it doesn't stay for long."
Moderna says on its website that while mRNA and gene therapy might sound similar, they "take fundamentally different approaches." The company wrote:
"Gene therapy and gene editing alter the original genetic information each cell carries. The goal is to produce a permanent fix to the underlying genetic problem by changing the defective gene ... Unlike gene editing and gene therapy, mRNA technology does not change the genetic information of the cell, and is intended to be short-acting."
In the same podcast episode, Rogan claimed that "its not supported by science" for people who have previously been sick with COVID-19 to get the shots. But public health experts recommend that people who have had COVID-19 already get immunized anyway, because the science shows they provide better and broader protection than natural immunity.
Rogan said the mRNA COVID-19 vaccines are "really gene therapy."
Thats wrong. The two interventions are not the same. Gene therapy involves modifying genes to cure or treat a disease.
The COVID-19 vaccines from Pfizer and Moderna use mRNA technology to instruct the cells to recognize a spike protein on the coronavirus and mount a response against it, but they make no changes to the recipients genetic makeup or DNA. The mRNA strands never enter the part of the cell that hosts DNA, and they are broken down soon after they are introduced into the body.
We rate Rogans claim False.
RELATED: Spotifys Joe Rogan repeats inaccurate claim that they are monitoring SMS texts
RELATED: Youth is not invincible: 9 experts dispute Joe Rogans vaccine advice for healthy 21-year-olds
- At FDA meeting, gene therapy experts wrestle with field's blindspots - BioPharma Dive - September 5th, 2021
- Astellas again hits pause on gene therapy trial - BioPharma Dive - September 5th, 2021
- Connecticuts Children first to enroll affordable gene therapy - WTNH.com - September 5th, 2021
- Cell And Gene Therapy Manufacturing Market Size Worth $57.4 Billion By 2028: Grand View Research, Inc. - PRNewswire - September 5th, 2021
- Global Gene Therapy Market Top Companies, Size, Growth Analysis, Segmentation, Industry Outlook Analysis , and Forecast 2020 to 2027 UNLV The Rebel... - September 5th, 2021
- Regenerative medicine 2021: report highlights record year for the sector - Clinical Trials Arena - September 5th, 2021
- Science Will Win Podcast: Season 1 - Pfizer - September 5th, 2021
- GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ -... - September 5th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and... - February 17th, 2021
- Avance Biosciences Expanding Houston Campus in Support of Cell and Gene Therapy Drug Development - BioSpace - February 17th, 2021
- Sensorion and Institut Pasteur announce new gene therapy collaboration - BioPharma-Reporter.com - February 17th, 2021
- Gene Therapy GS010 Safe, Well-Tolerated for LHON Patients - MD Magazine - February 17th, 2021
- bluebird bio 'baffled' after NICE rejects beta-thalassaemia gene therapy - - pharmaphorum - February 17th, 2021
- Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of... - February 17th, 2021
- GenSight Biologics' gene therapy proves safe in LHON trial - Clinical Trials Arena - February 17th, 2021
- Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire - February 17th, 2021
- Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions - OncLive - February 17th, 2021
- Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe... - February 17th, 2021
- CDMO Vigene plots cell and gene therapy manufacturing expansion, adding 245 new jobs along the way - FiercePharma - February 17th, 2021
- Taysha Gene Therapies Announces Formation of Independent Scientific Advisory Board - Business Wire - February 17th, 2021
- bluebird bio's beta-thalassaemia gene therapy rejected by NICE - PharmaTimes - February 17th, 2021
- Europe Cell and Gene Therapy Market Industry Outlook and Forecast Report 2021-2026 with Data-driven Insights on the Impact of COVID-19 -... - February 17th, 2021
- Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis -... - February 17th, 2021
- Rentschler Biopharma to build new cell and gene therapy capabilities in the UK - BioSpace - February 17th, 2021
- Gene Therapy Market to Reflect Impressive Growth Rate During 2020-2027 AveXis, Vineti, uniQure NV, Spark Therapeutics KSU | The Sentinel Newspaper -... - February 17th, 2021
- Genethon and WhiteLab Genomics Join Forces to Enhance Gene Therapy Through Artificial Intelligence - BioSpace - February 17th, 2021
- Avrobio Gene Therapy Shows Early Promise in Fabry, Other Rare Lysosomal Diseases - BioSpace - February 11th, 2021
- Global Genes Announces New Multimedia Series Focused on Advances in Gene Therapy and Editing, in Collaboration with the National Institutes of Health... - February 11th, 2021
- The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 20212026 - GlobeNewswire - February 11th, 2021
- FLT201 Shows Promise as a Gene Therapy for Gaucher Disease - MD Magazine - February 11th, 2021
- NICE Draft Guidance Recommends that Patients be Denied Access to bluebird bio's Gene Therapy for Life-Limiting Rare Blood Diseas - PharmiWeb.com - February 11th, 2021
- Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of... - February 11th, 2021
- Breakthrough gene therapy helps Utah boy thrive - Yahoo News - February 11th, 2021
- Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences - Yahoo Finance - February 11th, 2021
- Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market to 2030 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com - Yahoo... - February 11th, 2021
- Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium 2021 - GlobeNewswire - February 11th, 2021
- Paragon Biosciences Expands Cell And Gene Therapy Platform - Contract Pharma - February 11th, 2021
- FDA Clears IND Application for Passage Bio's Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare... - February 11th, 2021
- Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key... - February 11th, 2021
- FDA approves third gene therapy for large B-cell lymphoma - European Pharmaceutical Review - February 11th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - February 7th, 2021
- FDA Issues More Guidance on Gene and Cell Therapy Products - JD Supra - February 7th, 2021
- Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - BioSpace - February 7th, 2021
- The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis -... - February 7th, 2021
- AGTC Executives Awarded First Place in the BioProcess International Reader's Choice Awards, Cell & Gene Therapies Category - GlobeNewswire - February 7th, 2021
- Retinal Gene Therapy Market: Advent of High-end Technologies to Support Development of the Market - BioSpace - February 7th, 2021
- Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics - BioSpace - February 7th, 2021
- Welsh, Carson, Anderson & Stowe Commits $250 Million in a Strategic Partnership with Kiniciti, a Newly-Formed Platform Investing in Cell and Gene... - February 7th, 2021
- Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)... - February 7th, 2021
- Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium -... - February 7th, 2021
- Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss - Yahoo... - February 7th, 2021
- Meeting the commercialization challenge of a surging gene and cell therapy market - FierceBiotech - February 7th, 2021
- Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult - PharmiWeb.com - February 7th, 2021
- Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy - BioSpace - February 7th, 2021
- Avacta JV raises $7.3m for cell and gene therapy push | Business Weekly - Business Weekly - February 7th, 2021
- Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook - Business Wire - February 7th, 2021
- FDA's New Guidance on Cell and Gene Therapy Recommends Assessment of COVID-19 Transmission Risks - Lexology - February 7th, 2021
- After reeling back a gene therapy from Sanofi, a North Carolina upstart bags enough money to do something about it - Endpoints News - December 17th, 2020
- Gene Therapy in One Eye Improves Vision in Both Eyes - The Scientist - December 17th, 2020
- After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic - Endpoints News - December 17th, 2020
- Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics,... - December 17th, 2020
- Cell and Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change - GlobeNewswire - December 17th, 2020
- Passage Bio Invests In Gene Therapy Manufacturing R&D Site - Contract Pharma - December 17th, 2020
- Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -... - December 17th, 2020
- Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds - Forbes - December 17th, 2020
- What is gene therapy? - The Star Online - December 17th, 2020
- They thought their gene therapy failed. Instead, it spawned a medical mystery - Endpoints News - December 17th, 2020
- Health Canada approves Zolgensma, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA) - Canada NewsWire - December 17th, 2020
- Gene Therapy Injection in One Eye Improves Vision in Both - Technology Networks - December 17th, 2020
- Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies - BioSpace - December 17th, 2020
- Worldwide Gene Therapy Industry to 2025 - Cancer is Expected to Hold Significant Market Share in the Indication Segment - ResearchAndMarkets.com -... - December 17th, 2020
- Taysha Gene Therapies Set to Join Russell 2000 Index on December 21, 2020 - Business Wire - December 17th, 2020
- Rare Disease Gene Therapy Market: Increasing cases of genetic diseases to drive the market - BioSpace - December 17th, 2020
- Single gene therapy injection surprisingly boosts vision in both eyes - New Atlas - December 17th, 2020
- Freeline takes the haemophilia B gene therapy fight to Uniqure - Vantage - December 17th, 2020
- Gene Therapy for Hemophilia B Found Safe and Effective in First Phase III Trial - PRNewswire - December 14th, 2020
- ASH: UniQure/CSL hem B gene therapy curbs bleeding in phase 3even in patients with anti-AAV antibodies - FierceBiotech - December 14th, 2020
- Gene Therapy Market Analysis by Vector Type, Application, Region - Global Market Insights, Covid-19 Impact, Competition and Forecast to 2025 -... - December 14th, 2020
- Retinal Gene Therapy Market to Witness Sales Slump in Near Term Due to COVID-19; Long-term Outlook R - PharmiWeb.com - December 14th, 2020